Drug intelligence / Profile preview

lactobacillus acidophilus LB + atomoxetine

Development stage: Unknown
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus acidophilus LB + atomoxetine is a combination therapy consisting of the probiotic strain Lactobacillus acidophilus LB and the pharmaceutical agent atomoxetine. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). It works by increasing norepinephrine and dopamine levels in the prefrontal cortex, improving symptoms of ADHD. Lactobacillus acidophilus LB is a probiotic used to support gut health and maintain healthy intestinal flora. Recent clinical research has investigated this combination as an adjunctive treatment for ADHD, with evidence suggesting that adding L. acidophilus LB to atomoxetine may further improve ADHD symptomatology and cognitive performance compared to atomoxetine alone[1][2][3]. The mechanism behind this benefit may involve modulation of the gut-brain axis by probiotics, potentially influencing neurocognitive function.

Targets

NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on lactobacillus acidophilus LB + atomoxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus acidophilus LB + atomoxetine.

Explore the full profile